Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

November 20, 2006

Laser to drusen trial

This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Gaurav Shah, MD, Associate Professor of OphthalmologyGaurav Shah, MD
Associate Professor of Ophthalmology, Washington University Medical Center
Implications: It is not surprising that laser therapy is not effective for patients with macular degeneration. Initially there was a significant interest in this therapy, but as this well designed trial has shown us that thermal treatment is not the answer for dry ARMD. AREDS I and AREDS II are now the most important vitamin related studies with ARMD. The future for dry ARMD lies potentially with encapsulated compounds that may be delivered to the back of the eye for geographic atrophy. Currently the Anti-VEGF agents Lucentis and Avastin are the gold standard for wet ARMD. PDT in combination with these agents may be useful for decreasing the number in the injections involved.

Analysis:

This will have no impact on the way patients are currently treated.

 


Other Analyses of the Same Source Article:
AMD Prevention
November 17, 2006, Author: GLG Expert Contributor

Report a Concern

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T01:45:17.000